WO2012029076A3 - Stable pharmaceutical composition - Google Patents

Stable pharmaceutical composition Download PDF

Info

Publication number
WO2012029076A3
WO2012029076A3 PCT/IN2011/000594 IN2011000594W WO2012029076A3 WO 2012029076 A3 WO2012029076 A3 WO 2012029076A3 IN 2011000594 W IN2011000594 W IN 2011000594W WO 2012029076 A3 WO2012029076 A3 WO 2012029076A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
water insoluble
pharmaceutical composition
structural analog
close structural
Prior art date
Application number
PCT/IN2011/000594
Other languages
French (fr)
Other versions
WO2012029076A2 (en
Inventor
Ajay Jaysingh Khopade
N Arulsudar
Subhas Balaram Bhowmick
Bhushan Shrikant Borole
Original Assignee
Sun Pharma Advanced Research Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd. filed Critical Sun Pharma Advanced Research Company Ltd.
Publication of WO2012029076A2 publication Critical patent/WO2012029076A2/en
Publication of WO2012029076A3 publication Critical patent/WO2012029076A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition in the form of a solution comprising water insoluble therapeutically active ingredient and a close structural analog of the water insoluble active ingredient, one or more pharmaceutically acceptable excipients and one or more water miscible solvents wherein the water insoluble active ingredient is present in therapeutically effective amounts and the close structural analog is present in sufficient amounts such that when the composition is added to an aqueous vehicle it forms a nanodispersion suitable for intravenous infusion wherein said nanodispersion is stable for longer periods as compared to a dispersion formed from an identical composition but devoid of the close structural analog of the water insoluble active ingredient.
PCT/IN2011/000594 2010-08-30 2011-08-30 Stable pharmaceutical composition WO2012029076A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2180MU2010 2010-08-30
IN2180/MUM/2010 2010-08-30

Publications (2)

Publication Number Publication Date
WO2012029076A2 WO2012029076A2 (en) 2012-03-08
WO2012029076A3 true WO2012029076A3 (en) 2012-04-26

Family

ID=45773329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000594 WO2012029076A2 (en) 2010-08-30 2011-08-30 Stable pharmaceutical composition

Country Status (3)

Country Link
AR (1) AR082806A1 (en)
TW (1) TW201215412A (en)
WO (1) WO2012029076A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371201B (en) * 2013-10-04 2020-01-22 Prolynx Llc Slow-release conjugates of sn-38.
US20190209469A1 (en) * 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
AU2019206623A1 (en) 2018-01-12 2020-07-16 Prolynx Llc Synergistic cancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
WO2009101614A1 (en) * 2008-02-11 2009-08-20 Technion Research & Development Foundation Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US20100203150A1 (en) * 2009-02-06 2010-08-12 National Tsing Hua University Novel amphiphilic copolymers and fabrication method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
WO2009101614A1 (en) * 2008-02-11 2009-08-20 Technion Research & Development Foundation Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US20100203150A1 (en) * 2009-02-06 2010-08-12 National Tsing Hua University Novel amphiphilic copolymers and fabrication method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CREA ET AL.: "Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines", MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 7, pages 1964 - 1973; 2009-07-01 *

Also Published As

Publication number Publication date
WO2012029076A2 (en) 2012-03-08
AR082806A1 (en) 2013-01-09
TW201215412A (en) 2012-04-16

Similar Documents

Publication Publication Date Title
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2011107755A3 (en) Immediate/delayed drug delivery
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011012816A3 (en) Pharmaceutical formulation
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
WO2013129889A9 (en) High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2015075745A3 (en) Turmeric extract containing soft pastilles
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2012092486A3 (en) Modified release benzimidazole formulations
WO2012064302A3 (en) Improved montelukast formulations
WO2012127277A3 (en) Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2012029076A3 (en) Stable pharmaceutical composition
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11821222

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11821222

Country of ref document: EP

Kind code of ref document: A2